Expert Review of Neurotherapeutics最新文献_第2页

The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives. 体生长抑素类似物治疗神经内分泌肿瘤的现状和未来展望。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-16 DOI: 10.1080/14737175.2024.2417419

Eleonora Lauricella, Sofija Vilisova, Nada Chaoul, Andrea Giglio, Gabriella D'Angelo, Camillo Porta, Mauro Cives

{"title":"The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives.","authors":"Eleonora Lauricella, Sofija Vilisova, Nada Chaoul, Andrea Giglio, Gabriella D'Angelo, Camillo Porta, Mauro Cives","doi":"10.1080/14737175.2024.2417419","DOIUrl":"https://doi.org/10.1080/14737175.2024.2417419","url":null,"abstract":"Introduction: Somatostatin analogs (SSAs) were developed as antisecretory agents to palliate hormonal symptoms in patients with functioning neuroendocrine tumors (NETs). Their antiproliferative activity has been established in the phase 3 PROMID and CLARINET trials. SSAs currently represent the standard first-line therapy for the majority of well-differentiated G1/G2 gastroenteropancreatic NETs as well as for pulmonary NETs.Areas covered: An update on the clinical applications of established SSAs for the treatment of NETs is provided. Perspectives on emerging nonpeptide SSAs such as paltusotine and innovative formulations of octreotide (CAM2029) are included.Expert opinion: SSAs represent the cornerstone of treatment for both functioning and nonfunctioning NETs. While standard-dose SSAs have a defined place in the therapeutic algorithm of well-differentiated NETs, uncertainties remain on how to best integrate above-label doses of SSAs in the treatment sequence, particularly when tumor control is the goal. Octreotide and lanreotide appear to be clinically interchangeable, and no signs of superiority of one agent over the other has been observed so far. Whether SSAs may be exploited in the maintenance setting following more aggressive treatments, whether continuing SSAs beyond-progression after first-line therapy could be an effective treatment strategy, and whether new-generation SSAs such as pasireotide could overcome resistance to established SSAs are key areas of investigation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-14"},"PeriodicalIF":3.4,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why is the treatment and management of amyotrophic lateral sclerosis so difficult? 肌萎缩侧索硬化症的治疗和管理为何如此困难？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-11 DOI: 10.1080/14737175.2024.2415002

Philippe Corcia, Rachele Piras, Christian Lunetta

引用次数: 0

An overview of ganaxolone as a treatment for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. 伽那索隆治疗与细胞周期蛋白依赖性激酶样5缺乏症相关的癫痫发作概述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-07-31 DOI: 10.1080/14737175.2024.2385937

Alfie Gould, Sam Amin

{"title":"An overview of ganaxolone as a treatment for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder.","authors":"Alfie Gould, Sam Amin","doi":"10.1080/14737175.2024.2385937","DOIUrl":"10.1080/14737175.2024.2385937","url":null,"abstract":"Introduction: Cyclin-dependent kinase-Like 5 (CDKL5) deficiency disorder (CDD) is a rare neurodevelopmental condition commonly characterized by drug-resistant, refractory epilepsy, and seizures beginning in infancy. Most patients use multiple drugs, yet seizures remain difficult to control. So far, no conventional anti-seizure medications have been proven to be effective in individuals with CDD, in well-conducted studies.Areas covered: In this review, the authors assess the pharmacokinetics, early studies and appraise a recent study investigating the efficacy and safety of the oral suspension of ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) as an adjunctive therapy to treat seizures in CDD. The authors also discuss the impact of this drug on non-seizure outcomes.Expert opinion: Ganaxolone is a neuroactive 3β-methylated synthetic analogue of the potent agonist of gamma-aminobutyric acid type A receptors, allopregnanolone. Ganaxolone is the only drug that has been studied in a robust randomized controlled trial and been proven to be effective in this population.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"945-951"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging frontiers in Chronic Traumatic Encephalopathy: early diagnosis and implications for neurotherapeutic interventions. 慢性创伤性脑病的新前沿：早期诊断及对神经治疗干预的影响。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-08 DOI: 10.1080/14737175.2024.2385952

William Blanks, Marcus Hanshaw, Daniela A Perez-Chadid, Brandon Lucke-Wold

{"title":"Emerging frontiers in Chronic Traumatic Encephalopathy: early diagnosis and implications for neurotherapeutic interventions.","authors":"William Blanks, Marcus Hanshaw, Daniela A Perez-Chadid, Brandon Lucke-Wold","doi":"10.1080/14737175.2024.2385952","DOIUrl":"10.1080/14737175.2024.2385952","url":null,"abstract":"Introduction: Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disorder associated with repetitive head trauma. Historically, the diagnosis has been primarily clinical, which has hindered definitive early diagnosis and proactive intervention.Areas covered: The authors analyze the recent advancements in early diagnosis of CTE by examining biomarkers, imaging, and clinical decision tools. They discuss the identification of neuropathologies - such as tau aggregates - through novel techniques ranging from blood sampling and to brain density scanning. The reader will walk away with a better understanding of current advancements in early detection and be better equipped to deal with encephalopathies secondary to trauma in clinical practice.Expert opinion: Tremendous progress has been made in understanding the pathophysiology of CTE. Despite these advancements, CTE treatment is still primarily symptomatic rather than underlying disease. Future research should focus on integrating current understanding of CTE pathophysiology with treatment modalities.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"953-961"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and emerging pharmaceutical strategies for the treatment and management of restless legs syndrome. 治疗和管理不安腿综合征的现有和新兴药物策略。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-07-31 DOI: 10.1080/14737175.2024.2385947

Alessandra Burini, Gaia Pellitteri, Giovanni Merlino, Annacarmen Nilo, Yan Tereshko, Pierluigi Dolso, Gian Luigi Gigli, Mariarosaria Valente

{"title":"Current and emerging pharmaceutical strategies for the treatment and management of restless legs syndrome.","authors":"Alessandra Burini, Gaia Pellitteri, Giovanni Merlino, Annacarmen Nilo, Yan Tereshko, Pierluigi Dolso, Gian Luigi Gigli, Mariarosaria Valente","doi":"10.1080/14737175.2024.2385947","DOIUrl":"10.1080/14737175.2024.2385947","url":null,"abstract":"Introduction: Restless legs syndrome (RLS) is a sensory-motor sleep disorder that affects up to 13% of adults in the Western world and 2-4% of children. It impairs night sleep with an impact on daily performances and life quality. Thus, moderate-to-severe RLS requires pharmacological treatment.Areas covered: In the present review, which is based on PubMed searches with no time limits, the authors discuss the recommended pharmacotherapy for RLS in addition to other emerging treatment options. The authors provide coverage to the current recommendations for both adults and pediatric patients with RLS.Expert opinion: Current evidence suggests removing all causes of secondary RLS, including iron deficiency, chronic renal failure, drugs, and treating other sleep disorders that may worsen symptoms. Also, intermittent RLS should be addressed with behavioral measures and on-demand therapy. For chronic persistent RLS, α2δ calcium channel ligands are a first-line pharmacological approach, whereas dopamine agonists are associated with increased risk and should be spared. When RLS is refractory to first-line treatment, polytherapy, or opioid monotherapy should be considered. Nonetheless, some patients may not reach sustained symptom relief. Further research is needed to better understand the pathophysiology of RLS and to develop newer more effective drugs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"997-1009"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the pharmacological management of Tourette syndrome and emerging treatment paradigms. 图雷特综合征药物治疗和新兴治疗模式的最新进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-07-21 DOI: 10.1080/14737175.2024.2382463

Abhishek Lenka, Joseph Jankovic

{"title":"An update on the pharmacological management of Tourette syndrome and emerging treatment paradigms.","authors":"Abhishek Lenka, Joseph Jankovic","doi":"10.1080/14737175.2024.2382463","DOIUrl":"10.1080/14737175.2024.2382463","url":null,"abstract":"Introduction: Tourette syndrome (TS) is a childhood-onset neurobehavioral disorder characterized by tics. Pharmacotherapy is advised for patients whose symptoms affect their quality of life.Areas covered: The authors review the tic phenomenology and TS diagnostic criteria. The bulk of this article focuses on pharmacotherapeutic options for treating tics. They also highlight pharmacotherapies in the research pipeline.Expert opinion: Tic treatment must be tailored to individual needs. Behavioral therapy is the first line of treatment. Most with bothersome tics need pharmacotherapy and rarely, for medication-refractory cases, surgical therapy is indicated. Alpha-2 agonists are considered in patients with mild tics, especially in those with attention deficit with or without hyperactivity. Second-generation antipsychotics like aripiprazole and tiapride may be considered for severe tics. However, prescribers should be mindful of potential side effects, especially drug-induced movement disorders. Botulinum toxin injections may be considered for focal motor tics. Topiramate can be considered when other treatments are ineffective, and its benefits outweigh the risks. The same holds true for vesicular monoamine transporter-2 inhibitors, as they are deemed to be safe and effective in real-world use and open-label trials despite not meeting primary endpoints in placebo-controlled trials. Cannabinoids may be considered in adults if the approaches above do not control tics.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1025-1033"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why is ADHD so difficult to diagnose in older adults? 为什么诊断老年人多动症如此困难？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-04 DOI: 10.1080/14737175.2024.2385932

David W Goodman, Samuele Cortese, Stephen V Faraone

引用次数: 0

The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature. 髓鞘少突胶质细胞糖蛋白-免疫球蛋白 G 相关疾病（MOGAD）的药物治疗：文献更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-07 DOI: 10.1080/14737175.2024.2385941

Giuseppe Schirò, Salvatore Iacono, Giuseppe Salemi, Paolo Ragonese

{"title":"The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature.","authors":"Giuseppe Schirò, Salvatore Iacono, Giuseppe Salemi, Paolo Ragonese","doi":"10.1080/14737175.2024.2385941","DOIUrl":"10.1080/14737175.2024.2385941","url":null,"abstract":"Introduction: Myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD) is a clinical entity distinct from multiple sclerosis and aquaporin-4 (AQP4+)-IgG-positive neuromyelitis optica spectrum disorder. There is a lack of evidence regarding the efficacy and safety of current treatments used for MOGAD.Areas covered: In this article, the authors review the currently available literature on the pharmacological management of MOGAD. This article is based on an extensive search for articles including meta-analyses, clinical trials, systematic reviews, observational studies, case series and case reports.Expert opinion: Intravenous high-dose methylprednisolone is the most common therapy for acute attack with patients having a good treatment response. In cases with poor recovery, intravenous immunoglobulins (IVIG) or plasma-exchange proved to be effective. Maintenance therapies include mycophenolate mofetil, azathioprine, IVIG, oral corticosteroids, rituximab, and interleukin-6 receptor (IL6-R) antagonists. Rituximab is the most used drug while IL6-R antagonists emerged as an effective option for people not responding to current treatments. Larger prospective studies with longer follow-ups are needed to confirm whether the blockage of the IL6-R is an effective and safe option. Since there is no evidence of major safety issues related to the new available therapies, the authors believe that waiting for disease activity to consider a possible treatment change, is an unwise approach.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"985-996"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guidance on antipsychotic selection for agitation and aggressive behavior in persons with Huntington's disease. 亨廷顿氏病患者激动和攻击行为的抗精神病药物选择指南。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-07-09 DOI: 10.1080/14737175.2024.2376836

James E Eaton, Daniel O Claassen

引用次数: 0

Advances in the management of bipolar disorder in children and adolescents: an update on the literature. 儿童和青少年躁郁症的治疗进展：最新文献。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-05 DOI: 10.1080/14737175.2024.2386429

Andrea Amerio, Gabriele Arduino, Fabio Fesce, Alessandra Costanza, Andrea Aguglia, Mario Amore, Gianluca Serafini

{"title":"Advances in the management of bipolar disorder in children and adolescents: an update on the literature.","authors":"Andrea Amerio, Gabriele Arduino, Fabio Fesce, Alessandra Costanza, Andrea Aguglia, Mario Amore, Gianluca Serafini","doi":"10.1080/14737175.2024.2386429","DOIUrl":"10.1080/14737175.2024.2386429","url":null,"abstract":"Introduction: Early diagnosis and treatment concerning bipolar disorder (BD) are related to a better functioning over the long-term period. Although pharmacotherapy is indicated for approximately all youths with BD, nearly one-third of patients do not receive adequate medications for their condition.Areas covered: The authors discuss the available scientific evidence from the current literature about the management of BD in both children and adolescents, giving particular focus to the efficacy and tolerability of the available pharmacological agents. Studies were identified searching MEDLINE and retrieved from reference listings of relevant articles and through consultation with experts in the field.Expert opinion: Many D2-blockers, approved by the Food and Drug Administration (FDA) based on their antimanic properties in youths, are related to both short- and long-term side effects. Lurasidone was found to be effective for the treatment of acute juvenile bipolar depression, while lithium for the treatment and recurrence prevention of manic/mixed episodes. The most common anticonvulsants were found to be most useful as adjunctive antimanic agents in non-responders to first-line monotherapies. No data was found to support the use of antidepressants in juvenile BD.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1011-1024"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0